Caricamento...
End points and statistical considerations in immuno-oncology trials: impact on multiple myeloma
Unlike conventional cancer treatment, immuno-oncology therapies are commonly associated with delayed clinical benefit and durable responses, as seen with immuno-oncology therapies for multiple myeloma (MM). Therefore, a longer-term approach to immuno-oncology data assessment is required. Appropriate...
Salvato in:
| Pubblicato in: | Future Oncol |
|---|---|
| Autori principali: | , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Future Medicine Ltd
2017
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5705823/ https://ncbi.nlm.nih.gov/pubmed/28395525 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2217/fon-2016-0504 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|